Although recent literature and clinical guidelines increasingly support the use of CDK4/6i in the treatment of early-stage breast cancer, there is a lack of evidence regarding the safety of combining these agents with adjuvant RT, which typically involves moderate to high radiation doses. This evidence concerns the gene CDK4 and breast cancer.